ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Early Prediction of Hepatic Decompensation in Cirrhosis Using Optimised XGBoost Models at the Initial Outpatient Hepatology Visit.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- XGBoost-SHAP Interpretable Modeling Identifies and Validates an Eight-Gene Biomarker for Hepatic Encephalopathy Risk Prediction in Cirrhosis.International journal of molecular sciences · 2026Article
- Early Prediction of Hepatic Decompensation in Cirrhosis Using Optimised XGBoost Models at the Initial Outpatient Hepatology Visit.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatic decompensation represents a critical transition in cirrhosis, leading to increased morbidity, mortality and healthcare utilisation. Identifying patients at risk of decompensation remains a clinical challenge. We aimed to develop and validate XGBoost models to predict hepatic decompensation at multiple time points using clinical data available at a patient's initial outpatient hepatology visit.
methodsWe conducted a retrospective cohort study including 2208 adult patients with cirrhosis or its complications seen in hepatology clinics between 1985 and 2022. Patients were classified as compensated or decompensated based on a keyword search of the Philip and Ellie Kives Clinical Database, with decompensation dates confirmed by chart review. Sixteen routinely available variables including demographics, biochemical parameters and disease aetiology were used as predictors. Logistic regression and XGBoost models were trained to predict hepatic decompensation at 1, 3, 5 and 10 years, with a random 20% holdout test set used for validation. XGBoost models were tuned to optimise the precision-recall area under the curve (PR-AUC). Performance was evaluated using AUROC, precision, recall and F1 scores.
resultsXGBoost models outperformed logistic regression at most time points, demonstrating strong performance at 3 and 5 years. Recall was 0.42, 0.98, 0.98 and 0.82 at 1, 3, 5 and 10 years respectively. Corresponding AUROC values were 0.85, 0.88, 0.81 and 0.89.
conclusionsOptimised XGBoost models demonstrated robust predictive accuracy for medium- and long-term hepatic decompensation among patients with compensated cirrhosis. These models may support early risk stratification and enable personalised management strategies to prevent clinical deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.